Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Overview 7 Therapeutics Development 8 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Stage of Development 8 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Therapy Area 9 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Indication 10 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Companies 13 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Universities/Institutes 15 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 20 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Companies Involved in Therapeutics Development 22 AbbVie Inc. 22 Princeton University 23 Takeda Pharmaceutical Company Limited 24 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Drug Profiles 25 ABT-737 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 AT-101 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 navitoclax dihydrochloride - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 rottlerin - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 WEHI-539 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Dormant Projects 38 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Discontinued Products 42 Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Featured News & Press Releases 43 Apr 22, 2013: Walter And Eliza Hall Institute Scientists And Their Collaborators Develop New Potential Anti-cancer Compound WEHI-539 43 Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting 43 Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting 44 Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting 46 May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting 47 May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting 47 Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer 47 Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer 48 Jan 26, 2007: Abbott And Genentech Announce Global, Integrated Research, Development And Commercialization Collaboration In Oncology 49 Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia 50 Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting 51 Dec 12, 2005: Ascenta AT-101 Data Presented At The American Society Of Hematology 47th Annual Meeting And Exposition In Atlanta, Georgia 52 Dec 12, 2005: Ascenta AT-101 Data Presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, Georgia 53 Nov 18, 2005: Ascenta AT-101 Clinical Trial Data Presented At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer 54 Nov 10, 2005: Phase II Program Of Ascenta's Lead Product, AT-101, A Pan-inhibitor Of The Bcl-2 Protein Family, Begins 54 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56

List of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 18 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by AbbVie Inc., H1 2016 22 Pipeline by Princeton University, H1 2016 23 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 24 Dormant Projects, H1 2016 38 Dormant Projects (Contd..1), H1 2016 39 Dormant Projects (Contd..2), H1 2016 40 Dormant Projects (Contd..3), H1 2016 41 Discontinued Products, H1 2016 42 List of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Actions, H1 2016 18 Number of Products by Molecule Types, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 20

AbbVie Inc. Princeton University Takeda Pharmaceutical Company Limited